PE-backed Nexelis to buy ImmunXperts

Nexelis, a portfolio company of Ampersand Capital Partners, has agreed to acquire ImmunXperts, a Belgian provider of in-vitro immunology services.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this